PT - JOURNAL ARTICLE AU - M He AU - Z Lin AU - H Wang AU - Q Zhou AU - D Zou TI - EPV068/#398 Randomized controlled trial of the efficacy of adjuvant chemotherapy in patients with residual lesions after concurrent chemoradiation therapy for locally advanced cervical cancer (CQGOG0102) AID - 10.1136/ijgc-2021-IGCS.136 DP - 2021 Nov 01 TA - International Journal of Gynecologic Cancer PG - A56--A56 VI - 31 IP - Suppl 4 4099 - http://ijgc.bmj.com/content/31/Suppl_4/A56.1.short 4100 - http://ijgc.bmj.com/content/31/Suppl_4/A56.1.full SO - Int J Gynecol Cancer2021 Nov 01; 31 AB - Objectives The aim of this trial is to compare response rate and survivals of locally advanced stage cervical cancer patients with residual lesions who had Concurrent Chemoradiation therapy (CCRT) alone to those who had adjuvant chemotherapy after CCRT.Methods The CQGOG0102 study is a single-center, randomized controlled trial. The patients who have residual lesions after CCRT are randomized to arm A by observation or arm B by adjuvant chemotherapy with paclitaxel plus cisplatin every 3 weeks for 3 cycles.Results In our center, a retrospective study found that residual lesion after CCRT was one of the most important prognostic factors in patients with LACC. PFS and OS was decreased when the size of the residual lesion was over 10 mm. A further study showed that patients with residual lesion after CCRT treated with ACT had a significantly longer PFS compared to patients without ACT (22.4m vs. 12m, p <0.05). So, we designed the randomized controlled trial, CQGOG0102, to evaluate the efficacy of ACT in LACC with residual lesions after CCRT. At present, 30 patients have been enrolled. Pathological evidence of cervical residual lesion was identified in 23.3% (7/30). This trial is currently open and enrolling patients.Abstract EPV068/#398 Figure 1 Study designView this table:Abstract EPV068/#398 Table 1 Brief inclusion and exclusion criteriaConclusions ACT may improve the prognosis of LACC who has the residual lesion after CCRT. We will report the primary, midterm and final results about this study in the future. Clinical trial information: NCT04409860